Get notified when DCOY files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company explicitly states substantial doubt about its ability to continue as a going concern beyond Q2 2026, and auditors' reports include going-concern explanatory paragraphs.
Decoy Therapeutics files for up to $2.6M at-the-market offering at $5.66/share
Filed August 22, 2025 · ~1 min read
Key Changes
-
high
Decoy Therapeutics may sell up to $2.6 million of common stock from time to time through Ladenburg at market prices, with the last reported sale price at $5.66 per share.
The Offering verify on EDGAR → -
high
New investors will experience immediate dilution of $0.18 per share, as the pro forma net tangible book value per share is $5.48 versus the $5.66 offering price.
Dilution verify on EDGAR → -
high
The company's public float is only $9.16 million, limiting sales under this prospectus to one-third of that amount in any 12-month period.
The Offering verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade DCOY commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify